PHARMout Executive Team


Bih Hsu, Ph.D.

Dr. Hsu earned his Ph.D. in analytical chemistry specializing in mass spectrometry from Purdue University under the direction of Professor Graham Cooks. He has 30 years of experiences in pharmaceutical research and development primarily focusing on analytical chemistry and DMPK/Bioanalysis in both drug discovery and drug development. Dr. Hsu's work includes numerous projects that have led to NDA and MAA approval. Prior to Joining PHARMout Laboratories Dr. Hsu was the Vice General Manager of QR Pharmaceuticals in Wuhan, China as a head of research responsible for innovative and generic drug research. He was an executive director of DMPK/Bioanalysis and CMC Analytical chemistry at Exelixis Pharmaceuticals from 2004 to 2014. Dr. Hsu's expertise is mainly on GLP Bioanalysis, DMPK screening, GMP analytical, unknown/metabolite identification and characterization using advanced analytical technologies. He is versed in GLP and GMP regulation, IND, NDA and MAA filing.



Patrick Lin, Ph.D.

Dr. Lin has 30 years of scientific and managerial working experience in pharmaceutical research for both drug discovery and drug development. After earning his Ph.D. in analytical medicinal chemistry and constructing the first LCMS with electrospray interface at Purdue University for cataract proteomics research, Dr. Lin worked at MDS Pharma Services for 10 years as the Director and Senior Global Research Leader. He developed and validated GLP bioanalytical methods with more than one hundred publications and involved drug discovery and development for numerous pharmaceutical and biotech companies. Prior to partnering PHARMout Laboratories, Dr. Lin was the VP of Elim Biopharm to lead bioanalysis, and implement NextGen lab automation. He also previously was the Senior Director at Xenobiotic Laboratories, at Intertek to develop GLP/OECD facilities in China, and the co-founder of iPhase Pharma in Beijing, China. Dr. Lin is a member of SQA, ASMS and AAPS.



Allan Xu, Ph.D.

Dr. Xu obtained his PhD in biochemistry from University of Maryland at College Park in 1987. He has worked at both public and private sector laboratories for more than 30 years. Allan has pioneered the use and exploitation of mass spectrometry to provide analytical support for forensic, endocrinology, clinical toxicology, and pharmaceutical PK sample analysis. He is a co-founder at Keystone Bioanalytical, Inc. a LC/MS./MS based CRO located near Philadelphia where he held the position of Lab. Director since 1996. His main interest is using the most advance technology for small molecule/biomarker quantitation.



Wei Chen, Ph.D.

Dr. Chen has more than 20 years scientific experience in proteomics and DMPK research. She earned her PhD in Analytical/Physical Chemistry from University of British Columbia, Canada, under Prof. Don Douglas advice to develop mass spectrometer interfaces. She has since applied mass spectrometry to the research of proteomics and DMPK at varies research institutes from UVic-Genome BC Proteomics Centre, UBC Blood Research Centre, Cornell U. Proteomics Center to MD Anderson Cancer Center and at Revance Therapeutics as group leader. Dr. Chen is a member of ASMS and ABRF.


Copyright © 2019 Pharmout Laboratories, Inc. All rights reserved.